Journal Article Epublish
PubMed: 40364261 DOI: 10.3390/jcm14093230
Continuous Intravenous Insulin Infusion in Patients with Diabetes Mellitus After Coronary Artery Bypass Grafting: Impact on Glycemic Control Parameters and Postoperative Complications.
J Clin Med 14(9)
Authors: Alexey N Sumin, Natalia A Bezdenezhnykh, Dmitry L Shukevich, Andrey V Bezdenezhnykh, Olga L Barbarash
Affiliations
- Federal State Budgetary Scientific Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Academician L.S. Barbarash Boulevard, 6, Kemerovo 650002, Russia.
- Limited Liability Company "Family Health and Reproduction Center Krasnaya Gorka", Suvorova st. 3A, Kemerovo 650044, Russia.
- Department of Cardiology and Cardiovascular Surgery, Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University", Voroshilova st. 22A, Kemerovo 650056, Russia.
Abstract
Objectives: This study compared the efficacy of continuous insulin infusion therapy (CIT) versus standard bolus insulin therapy in maintaining optimal perioperative glycemic control in patients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG), focusing on postoperative outcomes. Methods: In this single-center, open comparative study, 214 T2DM patients were selected from 1372 CABG cases (2016-2018) and divided into CIT (n = 28) and bolus therapy (n = 186) groups. Both groups were matched for sex, age, smoking status, body mass index, functional class of angina or heart failure, surgical characteristics and preoperative HbA1c. The target glucose range was 7.8-10 mmol/L (140-180 mg/dL), consistent with current guidelines. Glycemic control was assessed through frequent postoperative measurements, with particular attention to glucose variability and hypoglycemic events. Results: The CIT group demonstrated superior glycemic control, with significantly lower median glucose levels at 7, 8, 10, 12, and 13 h post-CABG (p < 0.05). Glycemic variability was reduced by 32% in the CIT group (p = 0.012), and the incidence of hypoglycemia (<3.9 mmol/L) was 3.6% versus 8.1% in the bolus group. While overall complication rates were similar, the CIT group had 0 cases of stroke, myocardial infarction, or wound infections versus 2.7%, 3.2%, and 5.9%, respectively, in the bolus group. Logistic regression confirmed that each 1 mmol/L increase in first-day glucose levels independently predicted both significant (OR 1.20, 95% CI 1.06-1.36) and serious complications (OR 1.16, 95% CI 1.03-1.30). Conclusions: CIT provided more stable postoperative glycemic control with reduced variability and hypoglycemia risk in T2DM patients after CABG. Although underpowered to detect differences in rare complications, our findings suggest CIT may improve outcomes. These results warrant validation in larger randomized trials.
MeSH
Diabetes Mellitus, Insulin, Arteries, Coronary Artery Bypass, Therapeutics, Hypoglycemia, Postoperative Complications, Glycemic Control, Diabetes Mellitus, Type 2